Electric fields plus targeted radiation may boost survival in recurrent glioblastoma

NCT ID NCT07668869

Recruiting now Disease control Sponsor: Prof. Franciszek Lukaszczyk Memorial Oncology Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for adults with recurrent glioblastoma, an aggressive brain cancer. It tests whether adding a precise type of radiation (stereotactic radiosurgery guided by a special PET scan) to a device that delivers electric fields to the brain (TTFields) helps people live longer compared to using the device alone. About 92 participants will be randomly assigned to one of the two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor Treating Fields (TTFields) device and stereotactic radiosurgery
What this could lead to: If successful, this combination could offer a new, more effective treatment option for people with recurrent glioblastoma, potentially extending survival.
What could go wrong: This is a relatively small, early-phase trial. The added radiosurgery may not improve outcomes and could increase side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult glioblastoma glioblastoma IDH-wildtype glioblastoma syndromic X-linked intellectual disability Snyder type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE GLIOBLASTOMA MULTIFORME, ADULT

Contacts and locations

Locations

Department of Neurooncology and Radiosurgery, Franciszek Lukaszczyk Oncology Center
RECRUITING

Bydgoszcz, 85-796, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.